Literature DB >> 14605671

Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.

Luis E Raez1, Peter A Cassileth, James J Schlesselman, Swaminathan Padmanabhan, Eva Z Fisher, Paulette A Baldie, Kasi Sridhar, Eckhard R Podack.   

Abstract

Large tumor burdens in advanced non-small-cell lung carcinoma (NSCLC) are thought to be immunosuppressive. To determine whether CD8-mediated immune responses could be elicited in stage IIIB/IV NSCLC patients, 14 subjects were immunized several times with allogeneic NSCLC cells transfected with CD80 (B7.1) and HLA-A1 or A2. Patients enrolled were matched or unmatched at the HLA A1 or A2 locus and their immune response compared. Immunization significantly increased the frequencies of interferon-gamma secreting CD8 T cells in all but one patient in response to ex vivo challenge with NSCLC cells. The CD8 response of matched and unmatched patients was not statistically different. NSCLC reactive CD8 cells did not react to K562. Clinically, five of 14 patients responded to immunization with stable disease or partial tumor regression. The study demonstrates that CD8 Ifn-gamma responses against nonimmunogenic or immunosuppressive tumors can be evoked by cellular vaccines even at advanced stages of disease. The positive clinical outcome suggests that nonimmunogenic tumors may be highly susceptible to immune effector cells generated by immunization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605671     DOI: 10.1038/sj.cgt.7700641

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  5 in total

1.  Gp96 SIV Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa.

Authors:  Natasa Strbo; Monica Vaccari; Savita Pahwa; Michael A Kolber; Eva Fisher; Louis Gonzalez; Melvin N Doster; Anna Hryniewicz; Barbara K Felber; George N Pavlakis; Genoveffa Franchini; Eckhard R Podack
Journal:  Vaccine       Date:  2011-01-28       Impact factor: 3.641

2.  NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses.

Authors:  Philippe Krebs; Michael J Barnes; Kristin Lampe; Karen Whitley; Keith S Bahjat; Bruce Beutler; Edith Janssen; Kasper Hoebe
Journal:  Blood       Date:  2009-04-30       Impact factor: 22.113

3.  MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.

Authors:  Minu K Srivastava; Jacobus J Bosch; Ashley L Wilson; Martin J Edelman; Suzanne Ostrand-Rosenberg
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

Review 4.  Allogeneic tumor cell vaccines: the promise and limitations in clinical trials.

Authors:  Sanjay Srivatsan; Jaina M Patel; Erica N Bozeman; Imade E Imasuen; Sara He; Danielle Daniels; Periasamy Selvaraj
Journal:  Hum Vaccin Immunother       Date:  2013-09-24       Impact factor: 3.452

5.  Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.

Authors:  Minu K Srivastava; Jacobus J Bosch; James A Thompson; Bruce R Ksander; Martin J Edelman; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Immunother       Date:  2008-03-06       Impact factor: 6.968

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.